STADA Arzneimittel Stock

Equities

SAZ

DE0007251803

Pharmaceuticals

Delayed Xetra 5-day change 1st Jan Change
- EUR -.--% Intraday chart for STADA Arzneimittel -1.95% -8.87%
Manager TitleAgeSince
Chief Executive Officer 61 2018-08-31
Director of Finance/CFO - 2022-12-31
Chief Tech/Sci/R&D Officer 61 2014-12-31
Director TitleAgeSince
Director/Board Member 58 2017-09-25
Director/Board Member - 2017-09-25
Chairman 75 2017-09-26
Change 5d. change 1-year change 3-years change Capi.($)
-.--%-1.95% - - 5.73B
+0.81%+1.64%+7.94%+97.08% 46.76B
-1.49%+1.90%+71.63%+130.37% 37.97B
-0.32%+6.32%-4.67%+55.19% 12.14B
+2.02%+7.62%+11.83%+95.40% 10.44B
+4.12%+1.22%+37.95%+119.38% 9.13B
-1.55%+2.14%+69.81%-1.57% 7.65B
-1.03%-1.26%+20.19%+51.98% 7.53B
-0.63%-1.71%+60.74%+282.58% 6.91B
+1.50%+1.38%+170.00%+554.28% 6.31B
Average +0.34%+1.90%+49.49%+153.85% 15.06B
Weighted average by Cap. +0.14%+1.94%+39.24%+124.81%
Logo STADA Arzneimittel
STADA Arzneimittel AG is a Germany-based manufacturer of pharmaceuticals. The Company operates three business segments: Consumer Healthcare, Specialty Pharmaceuticals, and Generics. The Consumer Healthcare segment offers healthcare products for all categories includes cough and cold, derma, vitamins, minerals and gastro, pain and relief, women’s, and men's health through Nizoral, Zoflora, Grippostad, Silomat and Hirudoid brands. The Specialty pharmaceuticals segment delivers biological medicines, including biosimilars, offer treatment options for patients with chronic and disabling conditions including Cancer, osteoporosis, ophthalmic conditions and autoimmune diseases such as rheumatoid arthritis, Psoriasis and Crohn’s disease. The Generics segment is engaged in production and sales of inexpensive medicines that are known as generics. Its generic drugs are prescription products for the healthcare market that are sold under an International Nonproprietary Name (INN) brand.
Employees
-